March 2, 2023 — Englewood Health recently completed a single-center, investigator-initiated, FDA-approved clinical trial for Sonovein® echotherapy, a new noninvasive technology for treating varicose veins with therapeutic ultrasound.
Sonovein is the next evolution of a completely in-office, non-invasive, through-the-skin method of treating vein disease. For patients whose veins are conducive to this form of treatment, there are many advantages, including no incisions, guidewires, chemicals, or scars, and patients can resume normal activities immediately after the procedure.
Englewood Health accrued 20 cases of individuals with diagnosed symptomatic primary great saphenous vein (GSV) insufficiency, for this clinical trial. Results demonstrated a 95 percent success rate in treating GSV insufficiency, which is caused by incompetent veins and valves. This trial will now advance to a large multi-center trial led by Steve Elias, MD, Director of the Center for Vein Disease at Englewood Health, who was the principal investigator for this initial trial.
“All participating patients had an improved quality of life and reduction of symptoms,” said Dr. Elias. “These results are as good as, and in some cases better than, treatment with other more traditional technologies, and allows us greater choices when addressing each patient’s vein health needs.”
The Center for Vein Disease at Englewood Health is part of Englewood Health’s Vascular Surgery department, which is internationally recognized as a leading center for vascular and endovascular treatment.